-
2
-
-
0031695623
-
Age-specific prevalence and causes of blindness and visual impairment in an older population: The Rotterdam study
-
Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998;116:653-658. (Pubitemid 28414581)
-
(1998)
Archives of Ophthalmology
, vol.116
, Issue.5
, pp. 653-658
-
-
Klaver, C.C.W.1
Wolfs, R.C.W.2
Vingerling, J.R.3
Hofman, A.4
De Jong, P.T.V.M.5
-
3
-
-
0034788401
-
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and e and beta carotene for age-related cataract and vision loss: AREDS
-
Age-Related Eye Disease Study Research Group report no. 9
-
Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthal-mol 2001;119:1439-1452.
-
(2001)
Arch Ophthal-mol
, vol.119
, pp. 1439-1452
-
-
-
4
-
-
0027213771
-
Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization
-
Macular Photocoagulation Study Group
-
Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol 1993;111:1189-1199.
-
(1993)
Arch Ophthalmol
, vol.111
, pp. 1189-1199
-
-
-
5
-
-
3242663235
-
Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration
-
DOI 10.1097/00004397-200404430-00005
-
Barouch FC, Miller JW. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration. Int Ophthalmol Clin 2004;44:23-32. (Pubitemid 38955658)
-
(2004)
International Ophthalmology Clinics
, vol.44
, Issue.3
, pp. 23-32
-
-
Barouch, F.C.1
Miller, J.W.2
-
6
-
-
21744446220
-
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration
-
Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-368. (Pubitemid 40942262)
-
(2005)
Canadian Journal of Ophthalmology
, vol.40
, Issue.3
, pp. 352-368
-
-
Ng, E.W.M.1
Adamis, A.P.2
-
7
-
-
33749445317
-
Ranibizumab for neovascular age-related macular degeneration
-
DOI 10.1056/NEJMoa054481
-
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.14
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
Boyer, D.S.4
Kaiser, P.K.5
Chung, C.Y.6
Kim, R.Y.7
-
8
-
-
33749451356
-
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
-
DOI 10.1056/NEJMoa062655
-
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.14
, pp. 1432-1444
-
-
Brown, D.M.1
Kaiser, P.K.2
Michels, M.3
Soubrane, G.4
Heier, J.S.5
Kim, R.Y.6
Sy, J.P.7
Schneider, S.8
-
9
-
-
69249222585
-
A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration
-
Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116: 1731-1739.
-
(2009)
Ophthalmology
, vol.116
, pp. 1731-1739
-
-
Boyer, D.S.1
Heier, J.S.2
Brown, D.M.3
-
10
-
-
0024429725
-
Growth rate of subretinal neovascularization in age-related macular degeneration
-
discussion 1426-1429
-
Vander JF, Morgan CM, Schatz H. Growth rate of subretinal neovascularization in age-related macular degeneration. Ophthalmology 1989;96:1422-1426; discussion 1426-1429.
-
(1989)
Ophthalmology
, vol.96
, pp. 1422-1426
-
-
Vander, J.F.1
Morgan, C.M.2
Schatz, H.3
-
11
-
-
0024454362
-
Growth features of choroi-dal neovascular membranes in age-related macular degeneration
-
discussion 1420-1421
-
Klein ML, Jorizzo PA, Watzke RC. Growth features of choroi-dal neovascular membranes in age-related macular degeneration. Ophthalmology 1989;96:1416-1419; discussion 1420-1421.
-
(1989)
Ophthalmology
, vol.96
, pp. 1416-1419
-
-
Klein, M.L.1
Jorizzo, P.A.2
Watzke, R.C.3
-
12
-
-
21744461121
-
Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration
-
Oliver-Fernandez A, Bakal J, Segal S, et al. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 2005;40:313-319. (Pubitemid 40942258)
-
(2005)
Canadian Journal of Ophthalmology
, vol.40
, Issue.3
, pp. 313-319
-
-
Oliver-Fernandez, A.1
Bakal, J.2
Segal, S.3
Shah, G.K.4
Dugar, A.5
Sharma, S.6
-
13
-
-
80051657930
-
Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography
-
Grover S, Murthy RK, Brar VS, Chalam KV. Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci 2009.
-
(2009)
Invest Ophthalmol Vis Sci
-
-
Grover, S.1
Murthy, R.K.2
Brar, V.S.3
Chalam, K.V.4
-
14
-
-
33747782925
-
Ranibizumab: Phase III clinical trial results
-
DOI 10.1016/j.ohc.2006.05.009, PII S089615490600054X, Ocular Angiogenesis
-
Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19: 361-372. (Pubitemid 44279358)
-
(2006)
Ophthalmology Clinics of North America
, vol.19
, Issue.3
, pp. 361-372
-
-
Rosenfeld, P.J.1
Rich, R.M.2
Lalwani, G.A.3
-
15
-
-
38349172455
-
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascu-lar age-related macular degeneration: PIER Study year 1
-
Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascu-lar age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
-
(2008)
Am J Ophthalmol
, vol.145
, pp. 239-248
-
-
Regillo, C.D.1
Brown, D.M.2
Abraham, P.3
-
16
-
-
33846586501
-
Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration
-
DOI 10.1016/j.ophtha.2006.10.045, PII S0161642006014849
-
Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-252. (Pubitemid 46172497)
-
(2007)
Ophthalmology
, vol.114
, Issue.2
, pp. 246-252
-
-
Boyer, D.S.1
Antoszyk, A.N.2
Awh, C.C.3
Bhisitkul, R.B.4
Shapiro, H.5
Acharya, N.R.6
-
17
-
-
48449085770
-
A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations
-
Algvere PV, Steén B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008;86:482-489.
-
(2008)
Acta Ophthalmol
, vol.86
, pp. 482-489
-
-
Algvere, P.V.1
Steén, B.2
Seregard, S.3
Kvanta, A.4
|